

## Scientific Program

### BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00  
Thursday, October 10

Chair Persons: K.I. Panov, R. Fahraeus, R. Ketteler

- 200. The role of DNA topoisomerases in transcription of large ribosomal RNAs. S. Ray, T. Panova, G. Miller, A. Volkov, A.C.G. Porter, J. Russell, J.C.B.M. Zomerdijk, **K.I. Panov** (Belfast; Dundee; London, UK) (30')
- 176. The role of mRNA structures in the p53 signaling pathway. **R. Fahraeus** (Paris, France) (30')
- 151. High-complexity screening in 3D cancer model systems. J. Kriston-Vizi, C. Luft, J. Freeman, **R. Ketteler** (London, UK) (30')
- 154. Granzyme-B-mediated activation of procaspase-3 and its regulation in non-small cell lung carcinoma cells and tissues. **E. Krepela**, I. Rousalova, J. Prochazka, K. Benkova (Prague, Czech Republic) (30')

### SIGNAL TRANSDUCTION

Room A, 11:30-13:00  
Thursday, October 10

Chair Persons: T.G. Cotter, I. Sukhotnik, I. Mus-Veteau

- 221. Oncogene driven Redox signalling in tumour cells. **T.G. Cotter**, J. Stanicka, W. Landry (Cork, Ireland) (30')
- 111. The role of Wnt/ $\beta$ -catenin signaling during intestinal recovery following chemotherapy-induced mucositis. **I. Sukhotnik** (Haifa, Israel) (30')
- 150. The Hedgehog receptor Patched functions in multidrug transport and chemotherapy resistance. **I. Mus-Veteau**, L. Fiorini, E. Lalli (Valbonne, France) (30')

## CANCER THERAPEUTICS

Room A, 16:00-17:30  
Thursday, October 10

Chair Persons: E. Bremer, P.E. Nielsen, H. Modjtahedi

- 206. Antibody-based targeting of TNF-ligands for cancer therapy. **E. Bremer** (Groningen, The Netherlands) (30')
- 224. Peptide nucleic acid (PNA) antisense drug discovery from antibiotics to muscular dystrophy. **P.E. Nielsen**, C. Brolin, A. Ghosal (Copenhagen, Denmark) (30')
- 243. Co-targeting of HER family members and IGF-IR in pancreatic cancer. **H. Modjtahedi**, N. Ioannou, A. Dalgleish, D. Mackintosh, A.M. Seddon (Kingston; London, UK) (30')

## microRNAs

Room A, 18:00-19:30  
Thursday, October 10

Chair Persons: A.M. Piccinini, D.-G. Liu, M.A. Denti

- 120. Cross-talk between endogenous danger signals and microRNAs: Tenascin-C fine-tunes the immune response to infection via induction of miR-155. **A.M. Piccinini**, K.S. Midwood (London, UK) (30')
- 192. Tumor suppression by C/EBP $\beta$  3'UTR RNA: Functions and mechanisms. **D.-G. Liu** (Shanghai, P.R. China) (30')
- 223. MiRNAs as biomarkers of lung cancers. C. Cantaloni, M. Grasso, C. Asensi, S. Masella, L. Ricci, M. Barbareschi, **M.A. Denti** (Trento, Italy) (30')

## IMMUNOLOGY

Room B, 09:00-11:00  
Thursday, October 10

Chair Persons: T. Grundström, E. Ullrich, D. Dudziak

261. Mechanisms controlling diversification and affinity maturation of antibodies. J. Hauser, J. Verma-Gaur, A. Wallenius, C. Grundström, **T. Grundström** (Umeå, Sweden) (30')
279. Cellular immune regulation of GvL and GvHD following allogeneic stem cell transplantation. **E. Ullrich** (Frankfurt; Erlangen, Germany) (30')
299. Antigen targeting to dendritic cells as therapeutic option in the treatment of melanoma. K. Neubert, L. Heger, C.H.K. Lehmann, A. Baranska, A.M. Staedtler, V. Buchholz, S. Yamazaki, G.F. Heidkamp, N. Eissing, H. Zebroski, M.C. Nussenzweig, F. Nimmerjahn, **D. Dudziak** (Erlangen; Munich, Germany; Sapporo, Japan; New York, NY, USA) (30')
172. Tumor suppression by means of microenvironment-mediated stress response: The role of the human RNASET2 gene. **F. Acquati**, M. Lualdi, S. Bertilaccio, L. Monti, E. Pedrini, G. Turconi, A. Grimaldi, M. Fabbri, A. Anselmo, A. Inforzato, C. Riva, L. Gribaldo, P. Ghia, R. Taramelli (Varese; Milano; Ispra; Rozzano, Italy) (15')
185. Modeling inflammatory microenvironment: Stroma and antitumor immunity interactions. **L. Vannucci**, J. Krizan, F. Caja, D. Stakheev, L. Rajsiglova, P. Okenfuss, O. Chernyavskiy, R. Stepankova, J. Janacek, P. Vodicka, M. Levy, R. Matej, P. Makovsky, P. Rossmann (Prague, Czech Republic) (15')

## CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:00  
Thursday, October 10

Chair Persons: M.Z. Ratajczak, A. Semczuk

102. Bioactive lipids sphingosine-1-phosphate and ceramide-1-phosphate are pro-metastatic factors in human rhabdomyosarcoma cell lines, and their tissue level increases in response to radio/chemotherapy. G. Schneider, J. Ratajczak, M. Tarnowski, A.J. Morris, A. Vater, S. Klusmann, M. Kucia, **M.Z. Ratajczak** (Louisville, KY, USA; Szczecin, Poland; Berlin, Germany) (30')
219. Proliferative activity of primary uterine carcinosarcomas and corresponding metastases. **A. Semczuk**, J. Tomaszewski, A. Ignatov, M. Gogacz, K. Gałczyński, B. Marzec, M. Bogusiewicz, T. Rechberger (Lublin, Poland; Regensburg, Germany) (15')
106. Challenges in the management of stage III non-small-cell lung cancers. **W. Wagner**, A. Marra (Osnabrück; Ostercappeln, Germany) (15')
137. Aberrant AGR2 expression predicts worse patient outcome in poorly differentiated pancreatic ductal adenocarcinomas. **M. Hermanova**, V. Brychtova, J. Lenz, P. Karasek, R. Hrstka (Brno, Czech Republic) (15')
280. Carbonic anhydrase IX expression and biological aggressiveness of human cancers. M. Mascolo, G. Ilardi, M. Siano, M.L. Vecchione, F. Merolla, G. De Rosa, **S. Staibano** (Naples, Italy) (15')

## METASTASIS/PROGRESSION

Room B, 16:00-17:30  
Thursday, October 10

Chair Persons: M. Hutzler, W. Brenner

227. Neuropilin-1 is a key mediator of VEGF-dependent Treg migration to tumors. **M. Hutzler**, I. Helfrich, D. Schadendorf, J. Buer, W. Hansen (Essen, Germany) (15')
109. Bone metastasis in renal cell carcinoma is predicted by characteristics of the primary renal tumor. E. Schneider, T. Haber, F.C. Roos, K. Junker, C.C. Hampel, J.W. Thüroff, **W. Brenner** (Mainz; Homburg/Saar, Germany) (15')
158. Impact of CXCL12 - CXCR4/CXCR7 pathways in tumor-related angiogenesis: *In vitro* and *in vivo* validation. **C. Lehmann**, Y. Kienast, M. Thomas, F. Herting, S. Hart, M. Dangel, H. Huynh, N. Rieder, N. Dimoudis (Penzberg, Germany; Singapore) (15')
203. Integrins blocking and CXCR4 antagonism modulate cell invasion in glioma cancer stem cells. **S. Bertocchi**, M.C. Galiazzo, M. Paolillo, S. Schinelli (Pavia, Italy) (15')
204. Endothelial progenitor cells infiltration: Interplay between integrins and chemokines. **M.C. Galiazzo**, S. Bertocchi, M. Paolillo, S. Schinelli (Pavia, Italy) (15')
208. Targeting melanin for imaging and treatment of melanoma metastases. **D. Denoyer**, P. Lobachevsky, I. Greguric, R.J. Hicks (Melbourne; Sydney, Australia) (15')

## APOPTOSIS/HYPOXIA

Room B, 18:00-19:30  
Thursday, October 10

Chair Persons: O. Krizanova, I. Rousalova, H.M. Said

163. NF- $\kappa$ B inhibition in pheochromocytoma cell lines causes apoptosis: A novel therapeutic option? S. Hudcová, K. Pacák, A. Soltysová, **O. Krizanova** (Bethesda, MD, USA; Bratislava, Slovak Republic) (25')
186. Triptolide/Minnelide inhibits cell proliferation and induces apoptosis in non-small cell lung carcinoma. **I. Rousalova**, A.K. Saluja (Minneapolis, MN, USA) (25')
179. Carbonic anhydrase 9 modulation by the regulative effect of hypoxia and cytokines expression in hepatocellular carcinoma. **H.M. Said**, C. Hagemann, J. Anacker, M. Flentje, F. Kockar (Würzburg, Germany; Balikesir, Turkey) (25')
164. Isoproterenol accelerates apoptosis through the overexpression of the sodium/calcium exchanger in HeLa cells. **S. Hudcová**, L. Lencesová, L. Csáderová, J. Sedláková, M. Lauková, O. Krizanova (Bratislava, Slovak Republic) (15')

## EXPERIMENTAL CARCINOGENESIS

Room C, 09:00-11:00

Thursday, October 10

Chair Persons: M. Acevedo-Duncan, M.J. Ausserlechner

187. The PKC- $\iota$  inhibitor ICA-1 combined with TRAIL for glioblastoma therapy. A.N. McCray, S. Desai, **M. Acevedo-Duncan** (Tampa, FL, USA) (30')
298. Identification of novel XIAP inhibitors. M. Seiter, S. Salcher, M. Unger, P. Obexer, **M.J. Ausserlechner** (Innsbruck, Austria) (30')
282. What is the role of interstitial pH in diabetes mellitus? Improving action of propolis on type II diabetes mellitus via pH regulation. **Y. Marunaka**, W. Aoi, S. Hosogi, N. Niisato, N. Yokoyama, H. Hayata, H. Miyazaki, K. Kusuzaki, A. Taruno, T. Nomura (Kyoto, Japan) (30')
297. The role of splicing factors in glucocorticoid sensitivity in neoplastic lymphocytes. **A. Tanaka**, A. Matsuda, Y. Amagai, H. Matsuda (Tokyo, Japan) (30')

## MOLECULAR ONCOLOGY

Room C, 11:30-13:00

Thursday, October 10

Chair Persons: C. Rochais, H. Yamamoto

350. Tripentones, a promising anti-cancer family with a strong FLT3 affinity. **C. Rochais**, P. Dallemagne (Caen, France) (30')
262. Interleukin-18 may affect fibroblast growth factor 21 expression in tissue specific manner. **H. Yamamoto**, Y. Xu, K. Yamanishi, W. Li, Y. Okamatsu, M. Saito, H. Yamanishi, H. Okamura (Nishinomiya; Sapporo; Hirakata, Japan) (15')
236. pVHL maintains primary cilia stability by regulating the NEK-1 in renal cell carcinoma cells. X.-F. Ding, Q.-D. Yan, Y.-X. Qi, **G. Chen** (Taizhou, P.R. China) (15')
274. A new mechanism for coordinated regulation of protein synthesis, growth, and the cell cycle. **S. Pyndiah**, R. Fåhræus (Paris, France) (15')
349. The role of angiostatic CXCR3 chemokine ligands in cancer, as exemplified by CXCL4L1. **S. Struyf**, K. van Raemdonck, M. Gouwy, J. Vandercappellen, H. Verbeke, P. Proost, J. van Damme (Leuven, Belgium) (15')

## IMMUNOLOGY/MOLECULAR ONCOLOGY

Room C, 16:00-17:30  
Thursday, October 10

Chair Persons: Z. Balogi, N.A. Begum, S.N. Karagiannis

178. Diverting Hsp70 trafficking: A tool for stimulating the immune system against invading melanoma cells? K. Juhasz, B. Nimmervoll, R. Thuenauer, J. Hesse, T. Haselgrubler, P. Hinterdorfer, L. Vigh, A. Sonnleitner, L. Chtcheglova, **Z. Balogi** (Linz, Austria; Szeged, Hungary) (30')
235. Antibody gene diversification by AID requires specialized chromatin regulators. **N.A. Begum**, A. Stanlie, M. Aida, T. Honjo (Kyoto, Japan) (30')
301. Functional significance of antibody responses impairing anti-tumour immunity to melanoma. P. Karagiannis, A.E. Gilbert, F.O. Nestle, **S.N. Karagiannis** (London, UK) (30')

## CHEMOTHERAPY/PHARMACOLOGY

Room C, 18:00-19:30  
Thursday, October 10

Chair Persons: T. Eckschlager, M.P. Costi

155. Potentiation of cytostatics by histone deacetylase inhibitors (HDACi) - *In vitro* study. T. Groh, J. Hrabeta, M. Stiborova, **T. Eckschlager** (Prague, Czech Republic) (30')
296. Proteomic approach to the identification of early phase biomarker for anticancer peptides targeting the folate pathway. F. Genovese, A. Gualandi, L. Taddia, G. Ponterini, G. Marverti, S. Pirondi, R. Guerrini, M. Pelà, G. Pavesi, C. Trapella, **M.P. Costi** (Modena; Bologna; Ferrara, Italy) (30')
183. Ciglitazone enhances ovarian cancer cell death via inhibition of glucose uptake transporter-1. **C.-H. Cho**, S.-J. Shin, S.-H. Kwon, S.-D. Cha (Daegu, Republic of Korea) (15')
194. Evaluation of mRNA and protein expression of VEGF<sub>xxx</sub> and VEGF<sub>165b</sub> isoforms in head and neck squamous cells carcinoma. P.M. Biselli-Chicote, G.H. Marucci, R. Castro, B.R. Cunha, J.V. Maniglia, D.S. Neto, J.F. Góis-Filho, E.E. Fukuyama, É.C. Pavarino, **E.M. Goloni-Bertollo** (São José do Rio Preto; São Paulo, Brazil) (15')

## MOLECULAR MEDICINE

Room D, 09:00-11:00  
Thursday, October 10

Chair Persons: D.J. Timson, P.A. Ward

101. Galactosemia: From molecular causes to prediction and therapy. T.J. McCorvie, **D.J. Timson** (Belfast, UK) (30')
292. Role of IL-17 and IL-23 in septic shock. **P.A. Ward**, M. Bosmann (Ann Arbor, MI, USA; Mainz, Germany) (30')
130. Uptake of fluorescent desnitroso-streptozotocin analogs as a tool for the imaging of GLUT2-expressing cells. **W.J. Malaisse**, M. Virreira, I. Popescu, Y. Zhang, Y. Leshch, J. Thimm, J. Thiem, A. Sener (Brussels, Belgium; Hamburg, Germany) (15')
205. The hormetic effect of bilirubin: *In vitro* and *in vivo* evidence. **S.Y. Kim** (Seoul, Republic of Korea) (15')
118. Restoration of tumor suppressor Bax in MSI colon cancer. H. Zhang, B. Haferkamp, Y. Lin, X. Wang, M. Schultz, C. Tasson, **J. Xiang** (Chicago, IL, USA) (30')

## MOLECULAR MEDICINE

Room D, 11:30-13:15  
Thursday, October 10

Chair Persons: V. Papadopoulos, T. Takahashi

122. Function of the translocator protein TSPO in health and disease. **V. Papadopoulos** (Montreal, Canada) (30')
198. Protective role of heme oxygenase-1/CO system in hemorrhagic shock-induced acute lung injury. **T. Takahashi**, S. Kawanishi, J. Kosaka, H. Shimizu, H. Morimatsu (Okayama, Japan) (30')
177. The expression and intracellular trafficking of the P2Y-like receptor GPR17 in oligodendroglial cells. **P. Rosa**, A. Fratangeli, D. Lecca, V. Meraviglia, A. Ulivi, M. Fumagalli, L. Sironi, M.P. Abbracchio (Milan, Italy) (15')
230. Characteristics of bovine myeloid antimicrobial peptide (BMAP-28) as active antimicrobials. S. Takagi, **E. Isogai**, J. Nishimura, L. Bai, K. Kuroda, R. Suzuki, H. Yoneyama, S. Hayashi, H. Isogai (Sendai; Tochigi; Sapporo, Japan) (15')
426. Unpaired 3 is required for the self-renewal of both germ-line and somatic cyst stem cells in the *Drosophila* testis. M.H. Choi, Y. Cai, **G.H. Baeg** (Singapore) (15')

## MOLECULAR MEDICINE

Room D, 16:00-17:30  
Thursday, October 10

Chair Persons: C. Demonacos, M.Z. Gad

341. Differential control of oxidative stress and autophagy by sirtuin family members. **C. Demonacos**, R. Garva, M. Krstic-Demonacos (Manchester; Salford, UK) (30')
231. Suppressive effects of cationic antimicrobial peptides and mimics on colon cancer cell line HCT116 p53+/+ and p53-/- . **K. Kuroda**, T. Fukuda, H. Yoneyama, K. Okumura, H. Isogai, P.B. Savage, E. Isogai (Sendai; Hokkaido; Sapporo, Japan; Provo, UT, USA) (25')
108. Exploring genetic susceptibility to cardiovascular disease in Egyptians: Correlation to biochemical investigations. **M.Z. Gad**, S.I. Hassanein, M.F. Abdel Rahman, I.M. Hashad, S.M. Abdel-Maksoud, K. Abou-Aisha (Cairo, Egypt) (20')
263. Molecular analysis of prefrontal cortex in mice exposed to chronic mild stress; The influence on homeostasis in depressive state. **K. Yamanishi**, N. Doe, H. Yamamoto, Y. Xu, W. Li, M. Sumida, H. Yamanishi, H. Okamura, H. Matsunaga (Nishinomiya; Akashi; Hirakata, Japan) (15')

## CARCINOGENESIS/MOLECULAR ONCOLOGY

Room D, 18:00-19:30  
Thursday, October 10

Chair Persons: P. Soucek, A. Di Carlo

267. Biotransformation genes as prognostic markers in pancreatic adenocarcinoma. **P. Soucek**, B. Mohelnikova-Duchonova, V. Brynychova, V. Hlavac, M. Oliverius, E. Honsova, J. Mazanec, J. Hlavsa, Z. Kala (Prague; Plzen; Brno, Czech Republic) (30')
281. Gelatinolytic activities in sera and urine of human oncocytoma and renal cell carcinoma. **A. Di Carlo** (Rome, Italy) (15')
135. Molecular and genomic approach for understanding gene-environment interaction between Nrf2 deficiency and carcinogenic nickel-induced DNA damage. **Y.R. Seo** (Seoul, Republic of Korea) (15')
191. Potentiation of scutellarin on human tongue carcinoma xenograft by low-intensity ultrasound. **J. Zheng**, H. Li, Z. Gao, W. Cao (Harbin, P.R. China; University Park, PA, USA) (15')
342. Physical interaction between miR-155 and miR-146a gene loci: Co-regulation during macrophage activation and induction of endotoxin tolerance. **C. Doxaki**, A. Eliopoulos, C. Spilianakis, C. Tsatsanis (Heraklion, Greece) (15')

## EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00  
Friday, October 11

Chair Persons: S. Sarkar, W. Duan, M.M. Mrugala

- 143. Combination therapy of cancer by HDAC inhibitors and calpain inhibitor and epigenetic regulation of tumor suppressor genes. **S. Sarkar** (Boston, MA, USA) (30')
- 131. Targeting cancer stem cells *in vivo* using RNA aptamers. D. Xiang, S. Shigdar, **W. Duan** (Warun Ponds, Australia) (30')
- 234. Challenges and progress in the diagnosis and treatment of carcinomatous meningitis. **M.M. Mrugala** (Seattle, WA, USA) (30')
- 199. CD1760 (Thomsen-Friedenreich antigen) as a target for anti-tumor immunotherapy, from bench to bedside. **Y. Cao** (Kunming, P.R. China) (30')

## THERAPEUTICS/TUMOR MICROENVIRONMENT

Room A, 11:30-13:00  
Friday, October 11

Chair Persons: A. Richardson, P. Fishman

- 351. The potential for statins in the treatment of ovarian cancer. **A. Richardson**, E. Robinson (Keele, UK) (30')
- 396. Therapeutic effects mediated via the A3 adenosine receptor: From lab to label. **P. Fishman**, S. Cohen, S. Fishman, M. Farbstein, Z. Harpaz, M. Silverman (Petah-Tikva, Israel) (30')
- 336. Catalytic DNA as new drugs for cancer and vascular disease. **L.M. Khachigian** (Sydney, Australia) (30')

## EXPERIMENTAL THERAPEUTICS

Room A, 15:00-16:30  
Friday, October 11

Chair Persons: A. MacKenzie, M. Culty, D. Bachvarov

209. Exploring the impact of regulatory polymorphisms on drug response and disease; The future of stratified and personalised medicine? **A. MacKenzie**, P. Cowie, H. Bell (Aberdeen, UK) (30')
149. Gonocytes frozen in time: A look at the origins of testicular cancer. **M. Culty** (Montreal, Canada) (30')
244. DNA methylation alterations in ovarian cancer: Impact on cancer initiation, progression and response to therapy. **D. Bachvarov**, M. Keita, Z.-Q. Wang, J.-F. Pelletier, M. Bachvarova, M. Plante, J. Gregoire, M.-C. Renaud, A.-M. Mes-Masson, É.R. Paquet (Quebec; Montreal, Canada) (30')

## MOLECULAR ONCOLOGY/microRNAs

Room A, 17:00-18:30  
Friday, October 11

Chair Persons: L. Massaad-Massade, P. Bousquet, F.-S. Wang

232. New pharmacological approach by siRNA against junction oncogenes for thyroid and prostate cancers. G. Urbinati, A.M. Hafiz, **L. Massaad-Massade** (Villejuif, France) (25')
251. A structural and functional study of anti-ganglioside antibodies. **P. Bousquet**, N. Abshiru, R.F. Johansen, M. Bjørås, J.A. Sandvik, E.O. Pettersen, B. Thiede, R.J. Woods, E. Moreno, U. Krengel (Oslo, Norway; Athens, GA, USA; Havana, Cuba) (25')
241. MicroRNA-29a acts as a master regulator of osteogenic and chondrogenic potency in mesenchymal stem cells, osteoporotic bone and osteoarthritic joint microenvironments. **F.-S. Wang**, J.-Y. Ko, H.-J. Ke, Y.-S. Chen, Y.-C. Sun, M.-W. Chen (Kaohsiung, Taiwan, R.O.C.) (25')
202. MicroRNA-143 regulates chondrogenic differentiation of human mesenchymal stem cells. **J. Shang**, H. Liu, Y. Zhou (Chongqing, P.R. China) (15')

## POSTERS

POSTER VIEWING 18:30-19:30  
Friday, October 11

## HORMONES/THERAPEUTICS

Room B, 09:00-11:00  
Friday, October 11

Chair Persons: S. Thore, E. Castanas, G. Luo

326. Structural perspective on the steroid receptor RNA activator, a ncRNA with potential implication in breast cancer. F. Arieti, T. Huet, C. Gabus-Darlix, **S. Thore** (Geneva, Switzerland) (25')
322. Estrogen and androgen membrane receptors: Identification, signaling, transcription and pre-clinical pharmacology in breast and prostate cancer. M. Kampa, V. Pelekanou, G. Notas, E.N. Stathopoulos, **E. Castanas** (Heraklion, Greece) (25')
115. PLGA/poloxamer nanoparticle-encapsulated MBD1-siRNA effectively inhibits pancreatic cancer progression. **G. Luo**, Z. Xiao, Z. Liu, J. Long, X. Yu (Shanghai, P.R. China) (25')
156. Phospho-valproic acid (MDC-1112): A novel agent against pancreatic cancer. **G.G. Mackenzie**, L. Huang, N. Alston, N. Ouyang, K. Vrankova, G. Mattheolabakis, B. Rigas (Stony Brook, NY, USA) (15')
268. The anticancer action of novel estrogen-like compounds. **I. Zupkó**, R. Minorics, Á. Berényi, N. Bózsity, E. Mernyák, J. Wölfling, G. Schneider (Szeged, Hungary) (15')
366. A new highlight of resveratrol anticarcinogenic properties: Resveratrol metabolites as active compounds to inhibit human metastatic colon cancer cells progression. **D. Delmas** (Dijon, France) (15')

## SIGNALING

Room B, 11:30-13:00  
Friday, October 11

Chair Persons: L. Cocco, J. Brieger

277. Inositide-dependent PI-PLC $\beta$ 1 signalling from bench to bed side. **L. Cocco**, J.A. McCubrey, M.Y. Follo (Bologna, Italy; Greenville, NC, USA) (30')
110. Irradiation induced reactive oxygen radicals stimulate MAPK signalling, VEGF expression, and tumor cell survival. **J. Brieger**, M. Drigotas, A. Affolter, W.J. Mann (Mainz, Germany) (15')
323. The anti-inflammatory effect of estrogens on human peripheral monocytes is mediated through ER $\alpha$ 36. A. Deli, V. Pelekanou, M. Kampa, F. Kiagiadaki, P. Theodoropoulos, M. Michalodimitrakis, A. Tsapis, E. Castanas, **G. Notas** (Heraklion, Greece; Paris, France) (15')
321. The TNF-superfamily members APRIL and BAFF and their receptors (BAFFR, BCMA, TACI) are differentially expressed in a tissue and disease-specific manner in human solid tumors: Relation to cell fate and differentiation. **V. Pelekanou**, G. Notas, M. Kampa, V.-I. Alexaki, E.N. Stathopoulos, A. Tsapis, E. Castanas (Heraklion, Greece; Paris, France) (15')
246. *Ex vivo* analysis of pancreatic cancer infiltrating T cells reveals that ENO1-specific Tregs accumulate in tumor tissue and frustrate Th1/Th17 effector cell functions. **A. Amedei**, E. Niccolai, M. Benagiano, C. Della Bella, F. Cianchi, P. Bechi, L. Bencini, A. Taddei, P. Cappello, D. Prisco, F. Novelli, M.M. D'Elia (Florence; Turin, Italy) (15')

## DIAGNOSTICS

Room B, 15:00-16:30  
Friday, October 11

Chair Persons: K. Usuda, S.A. Lietman

105. Advantages of diffusion-weighted imaging over positron emission tomography-computed tomography in assessment of hilar and mediastinal lymph node in lung cancer. **K. Usuda**, M. Sagawa, N. Motono, M. Ueno, M. Tanaka, Y. Machida, M. Matoba, Y. Kuginuki, M. Taniguchi, Y. Ueda, T. Sakuma (Uchinada, Japan) (30')
165. Prognosticators in thigh soft tissue sarcomas. A.E. Newcomer, D. Wang, D. Dylinski, B.P. Rubin, B. Bershadsky, **S.A. Lietman** (Cleveland, OH, USA) (30')
142. Identification and characterization of novel pro-tumorigenic factors derived from cancer-associated fibroblasts. **M. Augsten**, F. Bruzzese, A. Saito, C. Peña, A. Östman (Stockholm, Sweden; Naples, Italy; Tokyo, Japan; Madrid, Spain) (15')
212. Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field. **M. Yozu**, P. Symmans, M. Dray, J. Griffin, C. Han, D. Ng, S. Parry, K.P. Wong (Auckland; Hamilton, New Zealand) (15')

## MOLECULAR MEDICINE

Room B, 17:00-18:30  
Friday, October 11

Chair Persons: D.L. Vesely, J. Xie, S. Mai

133. Inhibition of MAP kinases and oncogenes by cardiac hormones. **D.L. Vesely** (Tampa, FL, USA) (30')
141. Control of alternative splicing by external factors in cell physiology and disease therapy. **J. Xie** (Winnipeg, Canada) (30')
174. 3D nuclear organization and genomic instability. **S. Mai** (Manitoba, Canada) (30')

## EXPERIMENTAL THERAPEUTICS

Room C, 09:00-11:00  
Friday, October 11

Chair Persons: B.J. Jean-Claude, J. Peng, K. Nordlind

411. Tumour cell response to rationally designed epidermal growth factor receptor (EGFR) - c-Src targeting molecules. **B.J. Jean-Claude**, S. Rao, A.-L. Larroque (Montreal, Canada) (30')
123. The mechanism by which a traditional Chinese formula Pien Tze Huang treats colorectal cancer. A. Shen, Y. Chen, J. Lin, Q. Zhuang, L. Wei, H. Chen, Z. Hong, T.J. Sferra, **J. Peng** (Fuzhou, P.R. China; Cleveland, OH, USA) (30')
229. Alcohol and psoriasis - A possible role for tachykinins. **K. Nordlind**, L. Zou, S.-B. Lonne-Rahm, A. Helander, K. Stokkeland, J. Franck (Stockholm; Huddinge; Visby, Sweden) (30')
116. Down-regulation of Numb suppresses the growth and is correlated with poor prognosis of human hepatocellular carcinoma. **X. Xu**, C. Xie, G. Liu, J. Liu, Y. Yang, T. Zhang, Y. Deng, D. Wang, Z. Huang, F. Wang, X. Wu, X. Lei, X. Li (Changsha, P.R. China) (15')
275. Immunoprofile of patients with chronic myeloid leukaemia. **M. Petrackova**, Z. Humlova, H. Klamova, M. Duskova, V. Lucansky, I. Janatkova, M. Hindos, V. Vonka (Prague, Czech Republic) (15')

## INFLAMMATION/DIFFERENTIATION

Room C, 11:30-13:00  
Friday, October 11

Chair Persons: P. Swart, A. Akoum

167. Anti-inflammatory and anti-cancer activities of compound A: A synthetic compound derived from a natural product. **P. Swart**, A. Swart, A. Louw, K. De Bosscher, G. Haegeman, I. Budonova (Stellenbosch, South Africa; Ghent, Belgium; Chicago, IL, USA) (30')
327. Progesterone resistance in endometriosis: A plausible link to inflammation and abnormal ectopic endometrial tissue growth. **A. Akoum**, N. Michaud (Quebec, Canada) (30')
104. Anti-inflammatory and anti-fibrotic effects of JNJ7777120 and naproxen in an *in vivo* model of bleomycin-induced lung fibrosis. **A.C. Rosa**, A. Pini, L. Lucarini, R.T. Thurmont, D. Bani, E. Masini (Turin; Florence, Italy; San Diego, CA, USA) (15')
121. Chitinase-3-like-1 protein expression associated with pulmonary inflammation accelerates metastasis to the lung. S. Libreros, R. Garcia-Areas, R. Carrio, **V. Iragavarapu-Charyulu** (Boca Raton, FL; Miami, FL, USA) (15')

## BREAST CANCER

Room C, 15:00-16:30  
Friday, October 11

Chair Persons: M.A. Nagai, D. Marchetti, M. Zhang

- 293. Functional characterization of potential new biomarkers in breast cancer. **M.A. Nagai** (São Paulo, Brazil) (25')
- 126. The identification and characterization of breast cancer CTCs competent for brain metastasis. L. Zhang, L.D. Ridgway, M.D. Wetzel, J. Ngo, W. Yin, J.C. Goodman, M.D. Groves, **D. Marchetti** (Houston, TX, USA) (25')
- 139. Targeting tumor suppressor gene for breast cancer therapy. **M. Zhang**, N. Mahajan, H.Y. Shi (Chicago, IL, USA) (25')
- 182. DNA methylation in breast cancer. **H. Fiegl**, E. Müller-Holzner, G. Goebel, M. Widschwendter, P. Lirk (Innsbruck, Austria; London, UK; Amsterdam, The Netherlands) (15')

## BREAST CANCER

Room C, 17:00-18:30  
Friday, October 11

Chair Persons: L.M. Khachigian, E.M. Goloni-Bertollo

- 337. Inhibition of intimal thickening and acceleration of re-endothelialization after vascular injury using a cocktail approach. **L.M. Khachigian** (Sydney, Australia) (30')
- 218. Analysis of anti- and pro-angiogenic isoforms of VEGF in breast cancer. R. Castro, P.M. Biselli-Chicote, T.B. Castro, V.R. Regiani, S.P. Santo, D.S. Neto, N.A.B. Junior, J.L.E. Francisco, É.C. Pavarino, D.A.P.C. Zuccari, **E.M. Goloni-Bertollo** (São Paulo, Brazil) (15')
- 175. New small molecules targeting breast cancer. **J.A. Sakoff**, J. Gilbert, M. Tarleton, M. Robertson, A. McCluskey (New South Wales, Australia) (15')
- 159. Radiotherapy combined with multiple immune-modulatory antibodies ('radio-immunotherapy') cures mice bearing established mammary tumours. **I. Verbrugge**, J. Hagekyriakou, L.L. Sharp, M. Galli, A. West, N.M. McLaughlin, H. Duret, H. Yagita, R.W. Johnstone, M.J. Smyth, N.M. Haynes (Amsterdam, The Netherlands, East Melbourne; Parkville, Australia; San Diego, CA, USA; Tokyo, Japan) (15')
- 287. Development of an S-G2 micronucleus assay for the detection of *in vitro* chromosomal radiosensitivity in high-risk women subjected to early mammography screening for breast cancer. **A. Vral**, J. Depuydt, A. Baert, B. Poppe, T. van Maerken, F. Malfait, K. De Leeneer, M. D'Hooghe, K. Claes (Ghent; Brugge, Belgium) (15')

## HEMATOLOGICAL MALIGNANCIES/MOLECULAR ONCOLOGY

Room D, 09:00-11:00  
Friday, October 11

Chair Persons: E. Marcinkowska, N. Darwiche, H.-Y. Lan

136. Transcriptional regulation of vitamin D receptor and vitamin D-induced cell differentiation in acute myeloid leukemia cells. **E. Marcinkowska**, A. Marchwicka, E. Gocek, H. Burska, G. Brown (Wroclaw, Poland; Birmingham, UK) (25')
237. Retinoids for leukemia therapy: Beyond acute promyelocytic leukemia. **N. Darwiche**, R. Nasr, H. El Hajj, R. Hmadi, B. Khalil, A. Iskandarani, R. El-Eit, L. Vesci, C. Pisano, A. Bazarbachi (Beirut, Lebanon; Pomezia; Ariano Irpino, Italy) (25')
107. TGF- $\beta$  promotes cancer via Smad3-dependent microenvironments. **H.-Y. Lan**, S. Zhou, X.-M. Meng, G.-Y. Lian, X.-R. Huang (Hong Kong, P.R. China) (25')
125. The regulation of galectin-1 expression and its role in the differentiation of acute myeloid leukemic cells. **K.-W. Zhao**, X.-Y. Zhao, Y. Jiang, M. Zhao, G.-Q. Chen (Shanghai, P.R. China) (15')
129. PML-RAR $\alpha$  overexpression enhances autophagic activity, a role in leukemia pathogenesis. **Y. Huang**, J.-K. Hou, T.-T. Chen, X.-Y. Zhao, Z.-W. Yan, J. Zhang, J. Yang, S.C. Kogan, G.-Q. Chen (Shanghai, P.R. China; San Francisco, CA, USA) (15')
302. Role of FK506 binding protein 51 in human lymphomas. **M. Mascolo**, M.F. Romano, G. Ilardi, D. Russo, S. Varricchio, S. Romano, G. Pettinato, G. De Rosa, S. Staibano (Naples, Italy) (15')

## LUNG CANCER/BRAIN TUMORS

Room D, 11:30-13:00  
Friday, October 11

Chair Persons: S. Fischer, C.-W. Wu

380. Minimally invasive (VATS) resection for lung cancer: True innovation or marketing concept? **S. Fischer** (Ibbenbüren, Germany) (25')
157. Cancer stemness: Activation and role of stemness genes in lung cancer. **C.-W. Wu** (Taipei, Taiwan, R.O.C.) (25')
195. Comparative study of solitary thin-walled cavity lung cancer with computed tomography and pathological findings. **X.Y. Xue**, L. Pan, J.X. Wang (Beijing, P.R. China) (20')
220. Overexpression of LRIG3 inhibits growth and invasion of malignant glioma cell. **B. Wang**, H. Yang, Q. Xiao, B. Thomas, F. Ye, F. Wan, D. Guo, T. Lei (Wuhan, P.R. China) (20')

## COLON CANCER

Room D, 15:00-16:30  
Friday, October 11

Chair Persons: J. Hofmanová, V. Vymetalkova Polakova

169. Colon cancer cell lipidome and dietary lipids. **J. Hofmanová**, A.H. Vaculová, Z. Tylichová, N. Straková, B. Skender, J. Slavík, M. Ciganek, M. Machala, A. Kozubík (Brno, Czech Republic) (25')
171. Epigenetic regulation of relevant genes in sporadic colorectal cancer in the Czech Republic. **V. Vymetalkova Polakova**, J. Slyska, V. Korenkova, B. Pardini, M. Levy, A. Naccarati, P. Vodicka (Prague, Czech Republic; Turin, Italy) (20')
188. Transgelin may act as a transcriptional regulator in human colon cancer cells. **Y. Lin**, H.-M. Zhou, Y.-Y. Fang, Q.-K. Chen, H. Su (Guangzhou, P.R. China) (15')
215. Kiss-1 plays a suppressive role in the invasion and migration of colorectal cancer cells and the inhibition involves the regulation of MMP-9 via ERK signaling pathway. **K. Ji**, W.G. Jiang (Cardiff, UK) (15')
242. Role of VEGF and eNOS polymorphisms in predicting response and side-effects in metastatic colorectal cancer patients treated with bevacizumab. **P. Ulivi**, G. Marisi, A. Passardi, E. Scarpi, F. Casacci, D. Calistri, W. Zoli, G.-L. Frassinetti, D. Amadori (Meldola, Italy) (15')

## TUMOR BIOLOGY

Room D, 17:00-18:30  
Friday, October 11

Chair Persons: L. Holubec, J.L. Williams

368. The first clinical experience with cabazitaxel application in the II<sup>nd</sup> line of castration-resistant prostate cancer treatment. **L. Holubec**, J. Katolicka, J. Finek (Plzen; Pilsen; Brno, Czech Republic) (20')
285. Colon cancer racial health disparity and miRNA dysregulation. P. Ji, X. Wang, K. Shroyer, S. Burke, N. Davidson, Y. Zhang, E. Li, **J.L. Williams** (Stony Brook, NY; St. Louis, MO, USA) (20')
303. Starch based mucoadhesive microspheres for local targeting of colon cancer. **S. Akhter**, M.Z. Ahmad, F.J. Ahmad, G. Storm (Utrecht; Enschede, The Netherlands; New Delhi, India) (20')
180. Prostaglandin E2 promoted liver cancer cell growth and invasion. **X. Bai**, L. Zhang, J. Ma, M. Zhang, H. Zhang, S. Xia, J. Wang, M. Chen, J. Zhang, H. Jiang, H. Yang, Y. Guo, X. Ma, W. Huang, S. Cheng, R. Rong, Y. Wang, J. Leng (Nanjing, P.R. China) (15')
201. Caveolin-1 promotes the adhesion of hepatoma cells to Fn by up-regulating the levels of integrin  $\alpha 2,6$ -sialylation. **S. Wang**, S. Yu, J. Fan, L. Liu, L. Zhang, J. Zhang (Dalian, P.R China) (15')

## BIOCHEMISTRY/MOLECULAR BIOLOGY

Room E, 09:00-11:00

Friday, October 11

Chair Persons: P. Vodička, G. Peng, C.H. Nguyen

372. Chromosomal aberrations and cancer. **P. Vodička**, Z. Polívková, L. Mušák, S. Vodenková, P. Procházka, L. Vodičková, H. Demová, V. Poláková, M. Ambruš, M. Černá, R. Kumar (Prague, Czech Republic; Martin, Slovakia; Heidelberg, Germany) (30')
373. A molecular portrait of the homologous recombination DNA repair network via genome-wide transcriptome profiling. **G. Peng**, G.B. Mills, S.-Y. Lin (Houston, TX, USA) (30')
383. RGS2 and the cellular stress response. **C.H. Nguyen** (Buffalo, NY, USA) (30')
374. Discovery of oxysterols and small molecules as ligands for EBI2: A moving story. K. Niss-Arfelt, V. Daugliavite, T. Benned-Jensen, A.W. Sailer, **M.M. Rosenkilde** (Copenhagen, Denmark; Basel, Switzerland) (15')
376. Methoxy-resveratrol derivatives exert significant COX-1 and COX-2 inhibition that is differentially associated to the antiproliferative activity on lymphoma cells. **R. Frazzi**, M. Tigano, M. Chalal, V. Fragliasso, M. Coletta, N. Latruffe, D. Vervandier-Fasseur, F. Merli (Reggio Emilia, Italy; Dijon, France) (15')

## BREAST CANCER/THERAPEUTICS

Room E, 11:30-13:15

Friday, October 11

Chair Persons: Q. Yang, P.-H. Shen, R. Gambari

378. The multifaceted role of Metadherin in breast cancer. **Q. Yang**, N. Zhang, X. Kong, X. Li, Y. Zhao (Jinan, P.R. China) (30')
377. The influence of BCSG1 siRNA on gene expression of BCSG1 in human breast cancer and the expression of S-100A4, ETS1, VEGF and CD105 in human breast tumor. M. Guo, B. Liang, X. Li, X. Wang, **P. Shen** (Henan; Zhengzhou, P.R. China) (30')
389. miRNA therapeutics in cancer: Alteration of biological functions of oncomicroRNAs with peptide nucleic acids (PNAs). **R. Gambari** (Ferrara, Italy) (30')
420. Ribosomal proteins have multiple functions in DNA repair, cancer and cell cycle control. **J. Kim** (Seoul, Republic of Korea) (15')

## SIGNALING/TUMOR BIOLOGY

Room E, 15:00-16:30

Friday, October 11

Chair Persons: P.Z. Anastasiadis, M. Ackermann, L. Vodickova

375. Adhesion signaling in tumor progression. A. Kourtidis, L.R. Carpio, P. Pulimeno, T.R. Baker, R.W. Feathers, J.M. Carr, S.P. Ngok, J.C. Dachsel, E.A. Perez, P. Storz, J.A. Copland, E.A. Thompson, S. Citi, **P.Z. Anastasiadis** (Jacksonville, FL, USA; Geneva, Switzerland) (30')
386. Sprouting and intussusceptive angiogenesis in post-pneumectomy lung growth. **M. Ackermann**, J.P. Houdek, A. Ysasi, W. Wagner, J. Belle, A. Tsuda, S.J. Mentzer, M.A. Konerding (Mainz, Germany; Boston, MA, USA) (15')
387. Taste receptor gene variants and taste perception as tentative risk of determinants of colorectal cancer. **L. Vodickova**, M. Carrai, J. Slyskova, P. Prochazka, L. Bielik, S. Vodenkova, K. Jiraskova, A. Rejhova, V. Vymetalkova, R. Flamini, M. De Rosso, A. Dalla Vedova, L. Bavaresco, P. Vodicka, R. Barale (Prague; Pilsen, Czech Republic; Conegliano; Pisa, Italy) (15')
388. Targeting the histone methylating enzyme EZH2 for medulloblastoma therapy. I. Alimova, S. Venkataraman, P. Harris, N.K. Foreman, **R. Vibhakar** (Aurora, CO, USA) (15')
382. Tetraspanin CD81 contributes to melanoma invasion and metastasis by enhancing cell migrating ability through its positive effect on MT1-MMP expression. **H. Lee**, I.-K. Hong, H.-J. Byun (Chuncheon, Republic of Korea) (15')

## GYNECOLOGICAL CANCER/THERAPEUTICS

Room E, 17:00-18:30

Friday, October 11

Chair Persons: B. Kong, E. Karteris

379. The tubal origin of low-grade serous ovarian carcinoma. **B. Kong** (Jinan, P.R. China) (30')
381. Investigating the role of cortisol and oxytocin signalling in human ovarian cancer: When the stress hormone meets the social hormone. A. Rozeik, G. Pados, Y. Gidron, **E. Karteris** (London, UK; Thessaloniki, Greece; Brussels, Belgium) (30')
384. Protective effects of aspirin-triggered (17R) resolvins D1 and its analogue, 17R-hydroxy-19-para-fluorophenoxy-resolvins D1 methyl ester, in IgG immune complex-induced inflammation and lung injury. **H. Gao**, H. Tang, C. Yan, C.N. Serhan (Boston, MA, USA) (30')

## APOPTOSIS

Room A, 09:00-11:00  
Saturday, October 12

Chair Persons: D. Sliva, Y. Suzuki-Karasaki, D. Chandra

283. Triterpenes from mushroom *Poria cocos* induce proteotoxic stress and apoptosis in chemotherapy resistant human pancreatic cancer *in vitro* and *in vivo*. S. Cheng, I. Eliaz, **D. Sliva** (Indianapolis, IN; Sebastopol, CA, USA; Guangzhou, P.R. China) (30')
117. L-type Ca<sup>2+</sup> channels regulate apoptosis and TRAIL sensitivities in human melanoma and lung cancer cells. **Y. Suzuki-Karasaki** (Tokyo, Japan) (30')
233. Targeting apoptosome dysfunction for cancer therapy. **D. Chandra** (Buffalo, NY, USA) (30')
385. Regulation of chondrosarcoma cell survival and proliferation: New targets and strategies. Q. Jun, S. Irfan, L. Barré, **M. Ouzzine** (Vandœuvre-lès-Nancy, France) (30')

## BREAST CANCER

Room A, 11:30-13:00  
Saturday, October 12

Chair Persons: D.-X. Liu, G. Krupitza, Y.J. Jeong

152. Identification of biomarkers predicting endocrine therapy responsiveness in breast cancer. **D.-X. Liu** (Auckland, New Zealand) (30')
173. Mechanisms of breast cancer metastasis and the search for inhibitory drugs. **G. Krupitza** (Vienna, Austria) (30')
181. Molecular subtypes of breast cancer and DNA methylation patterns. **Y.J. Jeong** (Daegu, Republic of Korea) (30')

## EXPERIMENTAL THERAPEUTICS

Room A, 16:00-17:30  
Saturday, October 12

Chair Persons: W. Cao, J. Koch, A.V. Bazhin

190. Sonodynamic therapy inhibits angiogenesis and tumor growth. **W. Cao**, J. Zheng, Z. Gao, H. Li (Harbin, P.R. China; University Park, PA, USA) (30')
318. Inhibition of NKG2D-dependent immune escape for improved NK cell therapy of cancer. A. Groth, S. Weil, A. Steinle, U. Koehl, **J. Koch** (Frankfurt am Main; Hannover, Germany) (30')
324. Two immune faces of pancreatic adenocarcinoma: Possible implication for immunotherapy. **A.V. Bazhin** (Heidelberg, Germany) (30')

## TUMOR BIOLOGY/EPIGENETICS

Room A, 18:00-19:30  
Saturday, October 12

Chair Persons: J. Borlak, K.V. Rosen, W.G. Jiang

147. Dissecting epigenetic silencing complexity in the lung cancer suppressor gene *Cadm1*. S.M. Reamon-Buettner, **J. Borlak** (Hannover, Germany) (30')
248. Regulation of colon cancer cell survival by  $\beta$ -catenin. O. Masson, Y. Li, B.H. Yoo, **K.V. Rosen** (Halifax, Canada) (30')
213. *Yangzheng Xiaoji* in the treatment of solid cancers and the potential mechanism. **W.G. Jiang** (Cardiff, UK) (30')

## PROSTATE CANCER

Room B, 09:00-11:00  
Saturday, October 12

Chair Persons: N.A.P. Franken, P.S. Rennie, S. Assinder

- 119. Reduced expression of DSB repair genes in prostate cancer patients with late normal tissue radiation-toxicity. B. van Oorschot, P.D. Moerland, J.P. Medema, L.J.A. Stalpers, H. Vrieling, **N.A.P. Franken** (Amsterdam; Leiden, The Netherlands) (25')
- 161. Development of new drugs for targeting constitutively active, truncated forms of the androgen receptor found in castration resistant prostate cancers. K. Dalal, H. Li, E. Le Blanc, F. Ban, E. Guns, A. Cherkasov, **P.S. Rennie** (Vancouver, Canada) (25')
- 329. Differential effects of oxytocin in prostate cancer cell lines and *de novo* steroidogenesis. **S. Assinder**, A. Cole, K. Davies, M. Day, N. Tom (Sydney, Australia) (20')
- 166. 11 $\beta$ -hydroxyandrostenedione is metabolised to novel androgenic C19 steroids in the prostate. **A.C. Swart**, L.M. Bloem, L. Schloms, P. Swart, D. Africander, K.-H. Storbeck (Stellenbosch, South Africa) (20')
- 249. Cigarette smoke induces nuclear translocation of HO-1, enhancing the secretion of VEGF in prostate cancer cells. G. Birrane, H. Li, S. Yang, S. Tachado, **S. Seng** (Boston, MA, USA) (15')
- 286. Emerging second-line therapies for advanced, androgen deprivation-refractory prostate cancer in the post-docetaxel setting. **G. Perletti**, V. Magri, E. Marras, E. Monti, P.S. Rennie, A. Trinchieri, M.M. Neuberger, P. Dahm (Busto Arsizio; Milano; Lecco, Italy; Ghent, Belgium; Vancouver, Canada; Gainesville, FL, USA) (15')

## CANCER THERAPEUTICS/MOLECULAR ONCOLOGY

Room B, 11:30-13:00  
Saturday, October 12

Chair Persons: E.S. Patsouris, M. Krstic-Demonacos, A.K. El-Naggar

- 162. Personalized medicine and the future of pathology. **E.S. Patsouris** (Athens, Greece) (30')
- 348. Systems biology approaches towards developing personalized cancer therapeutics. **M. Krstic-Demonacos**, K. Tian, J.-M. Schwartz (Salford; Manchester, UK) (30')
- 410. Molecular pathology of salivary gland malignancies: Diagnostic and therapeutic implications. **A.K. El-Naggar** (Houston, TX, USA) (30')

## PHARMACOLOGY/EXPERIMENTAL ONCOLOGY

Room B, 16:00-17:30  
Saturday, October 12

Chair Persons: E.-S. Chen, L.A. Pardo, B. Köberle

103. A genome-scale molecular crosstalk governing chemoresistance against doxorubicin. Z. Tay, S.-H. Koo, R.-J. Eng, K.-K. Lim, M.-Y. Tang, K. Sajiki, M. Yanagida, E.J.D. Lee, **E.-S. Chen** (Singapore; Okinawa, Japan) (25')
306. Ion channels in cancer: Mechanisms, challenges and opportunities. **L.A. Pardo**, A. Sánchez, D. Urrego, F. Hartung, W. Stühmer (Göttingen, Germany) (25')
148. Overcoming cisplatin resistance in tumor cells. **B. Köberle**, V. Sen, A. Hartwig (Karlsruhe, Germany; Moscow, Russia) (25')
138. Cell-specific targeting to tumor stromal cells as a promising approach to treat cancer. R. Bansal, A. Ostman, G. Strom, K. Poelstra, **J. Prakash** (Enschede; Groningen; Utrecht, The Netherlands; Stockholm, Sweden) (15')

## TUMOR BIOLOGY

Room B, 18:00-19:30  
Saturday, October 12

Chair Persons: M. Jhanwar-Uniyal, N. Tsuchida, G. Vecchio

343. Epithelial to mesenchymal transition in metastatic brain tumors: Genes, proteins and targets of therapy. **M. Jhanwar-Uniyal** (Valhalla, NY, USA) (30')
228. Alpha-L-fucosidase (FUCA1) is a p53 target gene, and is expressed at low levels in anaplastic thyroid carcinomas. **N. Tsuchida**, M. Ikeda, S. Kanazawa, Y. Ishino, K. Kaji, G. Salvatore, M. Santoro, G. Vecchio (Tokyo; Fukuoka; Kyoto, Japan; Naples; Genoa, Italy) (15')
197. Downregulation of FUCA1 ( $\alpha$ -L-fucosidase) in human thyroid anaplastic carcinoma cell lines. **G. Vecchio**, C. Allocca, A. Parascandolo, A. Strazzulli, M. Moracci, M.D. Castellone, M. Santoro, N. Tsuchida (Naples; Genoa, Italy; Fukuoka; Tokyo, Japan) (15')
196. Quantitative proteomic analysis reveals a molecular triad signature as biomarker candidates for astrocytomas and oligodendrogliomas. **J.C. Rosa**, S.K.N. Marie, S. Oba-Shinjo, M. Gimenez (Sao Paulo, Brazil) (15')
265. Different roles of microRNA cluster miR-23a~24-2~27a in human cancers. **S. Jiang** (Guangzhou, P.R. China) (15')

## MOLECULAR ONCOLOGY/PHARMACOLOGY

Room C, 09:00-11:00  
Saturday, October 12

Chair Persons: E. Agostinelli, L. Vannucci

160. Lysosomotropic compounds sensitize apoptosis in cancer cells caused by spermine metabolites. Use of nanoparticles as delivery system in therapy. M. Meringolo, G. Tempera, M. Coccia, P. Matricardi, M. Condello, G. Arancia, A. Molinari, **E. Agostinelli** (Rome, Italy) (30')
184. Ferritin-based nanoparticles for specific targeting of melanoma: Results in mouse model. **L. Vannucci**, L. Rajsiglova, D. Stakheev, E. Falvo, J. Krizan, F. Caja, P. Rossmann, G. Carpinelli, P. Ceci (Prague, Czech Republic; Rome, Italy) (30')
189. Evaluation of the deoxyribonucleoside kinase of *Drosophila melanogaster* (Dm-dNK) as a suicide gene for treatment of solid tumors. **X. Zheng**, Y. Sun, X. Dong, L. Zhao, N. Zhang, S. Ma, M. Tang (Benxi; Shenyang, P.R. China) (30')
252. Expression of deltaNp73 isoform and its association with centrosome amplification in neurogenic tumor cell lines. **R. Veselska**, E. Mikulenкова, J. Neradil, K. Zitterbart, J. Sterba (Brno, Czech Republic) (30')

## CLINICAL ONCOLOGY/SURGICAL ONCOLOGY

Room C, 11:30-13:10  
Saturday, October 12

Chair Persons: S. Dragosavac, F. Timeus, H. Matsuda

114. PET/CT in ovarian cancer recurrence. **S. Dragosavac** (Sao Paulo, Brazil) (25')
266. NF-kappa B, a new target molecule in treatment of mesothelioma. S. Nishikawa, A. Tanaka, A. Matsuda, Y. Amagai, **H. Matsuda** (Tokyo, Japan) (20')
225. Association saquinavir-imatinib in the treatment of refractory neuroblastoma: A report of a single case. **F. Timeus**, E. Rivetti, S. Asaftei, M. Bianchi, C. Gabiano, P.A. Tovo, F. Fagioli (Turin, Italy) (15')
226. Saquinavir and ritonavir activity on neuroectodermal tumor cells. **F. Timeus**, N. Crescenzo, A. Doria, L. Foglia, S. Pagliano, L. Cordero di Montezemolo, P.A. Tovo (Turin, Italy) (15')
247. Recent advances in biomarkers for predicting cancer metastasis. **L. Ng** (Hong Kong, P.R. China) (15')

## MOLECULAR MEDICINE

Room C, 16:00-17:30  
Saturday, October 12

Chair Persons: F.M. Vallette, R.A. Wingert, K.K. McCampbell

- 317. Mesenchymal stem cells: The balance between death and differentiation. **F.M. Vallette**, L. Oliver (Nantes, France) (30')
- 333. Genetic analysis of kidney development using the zebrafish. **R.A. Wingert**, J. Cihlar, R. Bounds, M. McKernan, A. Fox, G.F. Gerlach (Notre Dame, IN, USA) (30')
- 334. Nephron regeneration after acute kidney injury in the zebrafish. **K.K. McCampbell**, R.A. Wingert (Notre Dame, IN, USA) (30')

## INFECTIOUS DISEASES

Room C, 18:00-19:30  
Saturday, October 12

Chair Persons: A. Brieger, E.T. Detorakis, G. Sourvinos

- 112. Is there an impact of hepatitis C virus on promoter hypermethylation of DNA mismatch repair genes? I. Hinrichsen, M. Kemp, S. Passmann, **A. Brieger** (Frankfurt, Germany) (15')
- 304. Viral involvement in the pathogenesis and clinical features of ophthalmic pterygium. **E.T. Detorakis**, A. Chalkia, D.A. Spandidos (Heraklion, Greece) (15')
- 245. Protein quality control and the Epstein-Barr virus-encoded EBNA1. **C. Daskalogianni**, S. Apcher, C. Voisset, M. Blondel, R. Farhaeus (Paris; Brest, France) (15')
- 284. Hepatitis B virus X protein upregulate miR-21 targets to PDCD4 suppress HCC cell apoptosis. X. Qiu, S. Dong, F. Qiao, S. Lu, Y. Song, Y. Lao, Y. Li, T. Zeng, L. Zhang, **H. Fan** (Nanjing; Hong Kong; Guangzhou; Jinan, P.R. China) (15')
- 338. Bactericidal ability of recombinant peptide of cationic antimicrobial peptides. **H. Isogai**, E. Isogai, K. Kuroda (Sapporo; Sendai, Japan) (15')
- 290. Impact of the Epstein-Barr virus latent infection on the course of chronic lymphocytic leukemia. **E. Grywalska**, J. Roliński, P. Grabarczyk, A. Goździcka-Józefiak (Lublin; Warsaw; Poznan, Poland) (15')

## MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room D, 09:00-11:00  
Saturday, October 12

Chair Persons: G.M. Das, G. Xu, J. Saczko

253. Interaction between estrogen receptor and tumor suppressor p53 in breast cancer: From basic research to clinical trial. **G.M. Das**, S.D. Konduri, S. Bansal, R. Medisetty, W. Liu, B.A. Kaiparettu, A. Sayed, S.A. Khan, M. Ip, H. Brauch, U.K. Mukhopadhyay, N. Wickramasekera, W.M. Swetzig (Buffalo, NY; Cincinnati, OH, USA; Stuttgart, Germany) (30')
257. Potential biomarkers for ovarian cancer. **G. Xu** (Shanghai, P.R. China) (30')
369. Modification of photodynamic therapy induced in cancer cells. **J. Saczko**, J. Weżgowiec, A. Choromańska, N. Rembiałkowska, M. Dubińska-Magiera, M. Kotulska, K. Biezuńska-Kusiak, J. Kulbacka (Wrocław, Poland) (30')
216. The role of sphingosine 1-phosphate in cancer. **S. Pyne**, J. Ohotski, S. Cochrane, F. Tonelli, K.G. Lim, R. Bittman, J. Edwards, N.J. Pyne (Glasgow, UK; New York, NY, USA) (15')
217. The role of sphingosine kinase in cancer. **N.J. Pyne**, F. Tonelli, K.G. Lim, M. Ossaimi, R. Bittman, J. Edwards, D.G. Watson, S. Pyne (Glasgow, UK; New York, NY, USA) (15')

## THERAPEUTICS/BREAST CANCER

Room D, 11:30-13:00  
Saturday, October 12

Chair Persons: N. Telang, W.G. Jiang, N. Pouliot

300. Efficacy of herbal extracts and constituent bio-active agents on models for genetically defined molecular subtypes of clinical breast cancer. **N. Telang**, M. Katdare (Montvale, NJ; Hampton, VA; Norfolk, VA, USA) (20')
214. New biomarkers in human breast cancer. **W.G. Jiang** (Cardiff, UK) (30')
207. Laminin-511: A key regulator of breast cancer metastasis. S. Onturk, X. Ling, N. Kusuma, R.L. Anderson, **N. Pouliot** (Melbourne; Parkville, Australia) (20')
295. Comparative analysis of factors effecting the dissemination of breast cancer diseases in different population groups of the Middle East. **D.A. Mohammed**, A.M.S. Amin, C. Hagemann, H.M. Said (Sulaimani, Republic of Iraq; Würzburg, Germany) (20')

## MOLECULAR ONCOLOGY

Room D, 16:00-17:30  
Saturday, October 12

Chair Persons: M. Libra, S. Demokan, K. Antoniou

355. Interactions between immune and environmental stimuli in non-Hodgkin lymphoma. **M. Libra**, F. Pezzino, S. Candido, R. Salemi, G. Malaponte, S. Trivali (Catania, Italy) (25')
325. Analysis of methylation biomarkers in head and neck cancer. **S. Demokan** (Istanbul, Turkey) (20')
316. Identification of the role of K<sub>V</sub>10.1 (Eag1) splice variants in tumors. **V. Romaniello**, F.R. Gomes, L.A. Pardo (Göttingen, Germany) (15')
332. Inhibition of tumor angiogenesis and growth by an oral extracellularly-acting small-molecule multi-FGF receptors blocker with allosteric properties. **C. Herbert**, F. De Smet, C. Alcouffe, D. Sibrac, M. Bianciotto, K. De Bock, U. Schieborr, K. Saxena, J. Juraszek, M. Georgiadou, C. Pendaries, G. Gueguen-Dorbes, I. Blanc, J.-P. Hérault, G. Lassalle, F.L. Gervasio, H. Schwalbe, P. Carmeliet, J.-M. Herbert, F. Bono (Toulouse, France; Leuven, Belgium; Frankfurt, Germany; Madrid, Spain) (15')
390. Expression of miR-93 and IL-8 during *Pseudomonas aeruginosa* infection of the human bronchial cystic fibrosis IB3-1 cells. **E. Fabbri**, M. Borgatti, N. Bianchi, A. Finotti, G. Montagnier, I. Lampronti, V. Bezzerri, M.C. Dehecchi, G. Cabrini, R. Gambari (Ferrara; Verona, Italy) (15')

## MOLECULAR MEDICINE

Room D, 18:00-19:30  
Saturday, October 12

Chair Persons: S.S. Signorelli, E. Rizos, L.M. Junie

357. Inflammation and peripheral arterial disease: Present and future. **S.S. Signorelli**, V. Fiore, G. Malaponte, M. Libra (Catania, Italy) (30')
397. MicroRNAs as biomarkers for schizophrenia cancer and other CNS disorders - The role of miR-183 as a possible molecular protective biomarker for cancer in schizophrenic subjects. **E. Rizos**, N. Siafakas, V. Zoumpourlis (Athens, Greece) (15')
398. miR-200 family miRNAs and miR-3069 expression is significantly differentiated between early and late mouse skin carcinogenesis stages. **E. Skourti**, C. Kontos, A. Scorilas, V. Zoumpourlis (Athens, Greece) (15')
339. The gene contents and the antibiotic resistance phenotypes of the *S. aureus* clinical isolates. **L.M. Junie**, L.M. Simon, M. Flonta, A. Almasanu, D. Homorodean, R. Ilie (Cluj Napoca, Romania) (30')

## MOLECULAR ONCOLOGY

Room E, 09:00-11:00  
Saturday, October 12

Chair Persons: K. Umezawa, G. Kulcsár

- 412. Protection of beta cells from cell death by NF-kappaB inhibitor (-)-DHMEQ via activation of Nrf2-Arf pathway. **K. Umezawa**, I. Takei (Nagakute; Ichikawa, Japan) (30')
- 413. Molecular design of epoxide-free (-)-DHMEQ analog that inhibits NF-kappaB and cytokine secretions. **K. Sidthipong**, S. Kobayashi, K. Umezawa (Nagakute; Noda, Japan) (15')
- 259. Experimental results supporting the role of certain small substances of the circulatory system in the defense against tumors and offering an interesting perspective in the treatment of cancer. **G. Kulcsár**, T. Czömpöly, D. Gaál, B. Mézes (Pécs; Budapest, Hungary) (30')
- 260. Preclinical and clinical exploration of the perspective to use small substances of the circulatory system in the treatment of cancer. **T. Czömpöly**, G. Kulcsár, D. Gaál, B. Mézes, Z. Langmár, M. Bors, C. Zsákai, M. Géczy (Pécs; Budapest, Hungary) (30')
- 210. Impact of polymorphisms in *DHFR*, *SHMT* and *DNMT3B* genes involved in folate metabolism in the risk of cancer of the head and neck. T.B. Castro, A.L.S. Galbiatti, R. Castro, L.S. Raposo, J.V. Maniglia, **É.C. Pavarino**, E.M. Goloni-Bertollo (São José do Rio Preto, Brazil) (15')

## MOLECULAR MEDICINE/ONCOLOGY

Room E, 11:30-13:05  
Saturday, October 12

Chair Persons: R. Gupta, S. Sifakis

- 340. Chemosensitizing effects of blueberry anthocyanidins. **R. Gupta**, F. Aqil, J. Jeyabalan, H. Kausar, M. Vadhanam, R. Munagala (Louisville, KY, USA) (20')
- 344. Analyses of serum VEGF in respect to FLT3 mutation in leukemia patients. **V. Jurisic**, N. Colovic, S. Pavlovic, M. Colovic (Kragujevac; Belgrade, Serbia) (15')
- 406. Calcium, magnesium and inorganic phosphate channels in preeclampsia. H. Yang, E.-J. Hong, **E.-B. Jeung** (Cheongju, Republic of Korea) (15')
- 140. An approach to nutrigenomics through epigenomics and lipidomics: Comparing lymphocyte PARP levels/hyperactivation and erythrocyte membrane lipid composition with life style and clinical profiles of patients undergoing endoscopic surveillance. A. Bianchi, M. Peluso, E. Barberis, S. Ruggiero, C. Formisano, G. Galloro, C. Ferreri, A. De Maio, **M.R. Faraone-Mennella** (Naples; Bologna, Italy) (15')
- 222. Change of fractions of hemoglobin depending on a carcinogenesis stage. **A. Sadvakas**, E.A. Tcherniavskaia, A.V. Saetchnikov (Almaty, Kazakhstan; Minsk, Belarus) (15')
- 417. Anti-VEGF maintenance therapy of patients with advanced metastatic colorectal carcinoma. **L. Holubec**, V. Liska, O. Fiala, J. Finek (Pilsen, Czech Republic) (15')

## POSTERS

113. Global expression analysis of microRNAs in paired initial and relapsed glioblastomas. **J. Sana**, A. Besse, R. Lakomy, L. Kren, Z. Kosarova, P. Fadrus, P. Slampa, M. Smrcka, R. Vyzula, O. Slaby (Brno, Czech Republic)
124. Slug-MT4-MMP axis induces formation of invadopodia in head and neck cancer cells. **W.-H. Yang**, H.-Y. Lan, M.-H. Yang (Taipei, Taiwan, R.O.C.)
127.  $\gamma$ -tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF- $\kappa$ B-regulated anti-apoptotic gene products. **K. Kani**, Y. Momota, H. Takano, Y. Yamamura, K. Aota, K. Motegi, M. Azuma (Tokushima, Japan)
128. A positive feedback loop between Snail and TNF- $\alpha$  promotes tumor invasiveness through acetylation of Snail. **D.S.-S. Hsu**, H.-J. Wang, M.-H. Yang (Taipei, Taiwan, R.O.C.)
132. *In vivo* HCC gene therapy targeting by *trans*-splicing ribozyme and liver specific promoter with augmented safety. **J.S. Jeong**, S.Y. Han, I.H. Kim, S.W. Lee (Busan; Goyang; Jukjeon, Republic of Korea)
134. Construction of recombinant adenoviruses expressing miRNA against GRP78 in HepG2 cells. **L.-F. Wu**, Y.-T. Guo, H.-B. Li, Q.-H. Zhang, Y.-Q. Ye, Z.-J. Pu, J.-L. Feng (Shantou, P.R. China)
144. Epigenetic regulation of tumor suppressor genes including imprinted gene ARHI and micro-RNAs in cancer cells. **S. Byler**, S. Goldgar, S. Heerboth, S. Rosenthal, S. Kokolus, S. Sarkar (Boston, MA, USA)
145. Mechanism of DNMT1 downregulation in the demethylation and reexpression of tumor suppressor genes. **S. Heerboth**, S. Rosenthal, N. Tatur, K. Lapinska, S. Kokolus, S. Sarkar (Boston, MA, USA)
146. Anticancer effects of histone deacetylase inhibitors and calpain inhibitor. **K. Lapinska**, G. Housman, S. Heerboth, M. Longacre, S. Sarkar (Boston, MA, USA)
153. SHON is a novel biomarker predicting breast cancer response to endocrine therapy. **D.-X. Liu**, T.M.A. Abdel-Fatah, Y. Jung, C.C. Nolan, B. Huang, J. Lu, J.K. Perry, S.Y.T. Chan, A.R. Green, I.O. Ellis (Auckland, New Zealand; Nottingham, UK)
168. Thymidine phosphorylase immunostaining in 182 patients with uterine cervical cancer: Prognostic significance of expression in tumor and stromal cells. **K. Yamamoto** (Osaka, Japan)
170. Experimental study of expression of *MTHFR*, *DHFR*, *TYMS* and *SLC19A1* folate genes in laryngeal cancer cell line administered with methotrexate chemotherapy in three different doses. **A.L.S. Galbiatti**, H.C. Caldas, R. Castro, J.A. Padovani-Junior, É.C. Pavarino, E.M. Goloni-Bertollo (Sao Paulo, Brazil)
193. Mab's to La-Sota strain in the production and control of Newcastle Disease Virus for the therapy of tumors. **V.K. Sologub**, I.A. Koromyslova, V.V. Keshelava (Moscow, Russia)
211. Quercetin improves insulin resistance and hepatic lipid accumulation in a NAFLD cell model. **X. Li**, R. Wang, N. Zhou, X. Wang, Q. Liu, Y. Bai, Y. Bai, Z. Liu, H. Yang, J. Zou, H. Wang, T. Shi (Chifeng, Inner Mongolia; Beijing, P.R. China)
238. Medulloblastoma subcategories as identified by molecular markers differ in tumor tissue and in corresponding cell lines. **P. Chlapek**, L. Filipova, K. Zitterbart, J. Sterba, R. Veselska (Brno, Czech Republic)
239. CXCR4 expression in sarcoma derived cell lines. **J. Neradil**, H. Kockova, I. Zambo, M. Hermanova, K. Husek, P. Mudry, K. Zitterbart, J. Sterba, R. Veselska (Brno, Czech Republic)
240. Acute phase reaction in patients with colon carcinoma surgery and plasma miRNA levels (a pilot study). **J. Kvasnicka**, Z. Krska, U. Jan, K. Zichova, T. Kvasnicka, V. Cverhova (Prague, Czech Republic)
250. Methylation profile of P16 in head and neck cancer. **L.M.R.B. Arantes**, M.E. Melendez, E.H. Tajara, E.M. Goloni-Bertollo, A.L. Carvalho (São José do Rio Preto; Barretos, Brazil)
254. BJcuL, a C-type lectin from *Bothrops jararacussu* venom, sensitizes colorectal adenocarcinoma cell line to TRAIL. **L. De F.C. de M. Zischler**, D.C. Damasio, S. Nolte, N.B. Bonan, N. Dotti, L. De Noronha, A.N. Moreno-Amaral, S. Elifio-Espósito (Curitiba, Brazil)

255. The mechanism of action of targeted cytotoxic LHRH analog AN-152 (AEZS-108) in human uveal melanoma cells. **A. Treszl**, K. Fodor, A.V. Schally, Z. Steiber, G. Oláh, G. Halmos (Debrecen, Hungary; Miami, FL, USA)
256. Design, synthesis and *in vitro* evaluation of <sup>18</sup>F-labeled luteinizing hormone-releasing hormone (LHRH) analog for cancer visualization. **I. Kertész**, D. Rózsa, G. Oláh, G. Trencsényi, T. Márián, A. Treszl, G. Mező, G. Halmos (Debrecen; Budapest, Hungary)
258. Doxorubicin-induced drug resistance is mediated by the p38 MAPK pathway in human leukemia K562 cells. **Y. Chen**, G. Xu (Shanghai, P.R. China)
264. CpG ODN enhances radiosensitivity mediated by ATM phosphorylation in human lung adenocarcinoma A549 cells. **T. Qiao**, X. Liu, G. Xu (Shanghai, P.R. China)
269. 17alpha-19-nortestosterone exhibits potent antiproliferative effect in HeLa human cervical cancer cells. **R. Minorics**, N. Bózsity, Z. Benkő, E. Mernyák, J. Wölfling, G. Schneider, I. Zupkó (Szeged, Hungary)
270. Nanosecond pulsed electric fields (nsPEFs) in combination with photodynamic reaction with Photofrin in human cancer and normal cell lines. **J. Kulbacka**, J. Saczko, A. Choromańska, M. Dubinska-Magiera, P. Surowiak, M. Kotulska (Wroclaw, Poland)
271. Expression of Bcl-2 and other regulatory genes in primary cell culture derived from spinocellular tumour of head and neck. **J. Gumulec**, M. Sztalmachova, H. Polanska, M. Holubova, J. Balvan, K. Hudcova, H. Binkova, Z. Horakova, R. Kostrica, M. Raudenska, O. Zitka, V. Adam, R. Kizek, M. Masarik (Brno, Czech Republic)
272. Metallothionein as a spinocellular tumour biomarker: Analysis of tumorous tissue samples. **J. Gumulec**, M. Sztalmachova, H. Polanska, M. Holubova, J. Balvan, H. Binkova, Z. Horakova, R. Kostrica, O. Zitka, V. Adam, R. Kizek, M. Masarik (Brno, Czech Republic)
273. Establishment and characterization of three mesothelioma models derived from primary patient tumours. **C. Pisano**, A. Cole, M. Barbarino, E. Bianchino, M. Guglielmi, I. La Porta, C. Melito, G. Mercadante, A. Riccio, P. De Luca (Ariano Irpino, Italy)
276. Antineoplastic effects of tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of survivin transcription, in medulloblastoma cells. **A.M. Castro-Gamero**, A.F. Andrade, M.M. Fujinami, R. De Paula Gomes Queiroz, C.A. Scrideli, L.G. Tone (Sao Paulo, Brazil)
278. Resveratrol induces apoptosis in melanoma cells via downregulation of survivin expression. **I. Saiki**, Habibie, S. Abdelhamed, S. Awale, Y. Hayakawa, S. Yokoyama (Toyama, Japan)
288. Novel STAT3 phosphorylation inhibitor ameliorates dextran sulfate sodium-induced colonic inflammation in mice. **Y. Chen**, J. Eckert, J. Thorpe, B. Disch, P.-K. Li, C. Li, R.M. Gallucci, M. Ihnat, T.J. Sfera (Cleveland, OH; Oklahoma City, OK; Columbus, OH, USA)
289. Effect of metformin on markers of epithelial mesenchymal transition induced by TGF-beta in mammary cells. **C. Leonel**, D. Ap. Pires de Campos Zuccari, A. Vilorio-Petit (São José do Rio Preto, Brazil; Guelph, Canada)
291. Regulation of peroxisomal function by C10orf10/DEPP. S. Salcher, J. Hagenbuchner, M.J. Ausserlechner, **P. Obexer** (Innsbruck, Austria)
294. Transcriptome profiling of MCF7 cells with different expression pattern of SPARC (secreted protein acidic in rich in cysteine) in the presence and absence of docetaxel. A.C. Pavanelli, F.R.R. Mangone, **M.A. Nagai** (São Paulo, Brazil)
305. Human serotonin receptors and transporter gene variants in association with heparin induced thrombocytopenia. **G. Soufla**, E. Iliopoulou, A. Aggelidis, M. Katafygioti, N. Matoula, I. Melissari, E. Melissari (Athens, Greece)
307. Kv10.1 expression impairs ciliogenesis. **A. Sánchez**, L.A. Pardo (Göttingen, Germany)
308. 5a (+)/5a (-) variants of ADAR2 expression ratio correlates with malignant features in gliomas. J. Wei, Z. Li, C. Du, X. Zhao, H. Fu, **Y. Tian** (Changchun, P.R. China)
309. Identification and characterization of alternative splicing pattern of ADAR2 in human glioma cell lines. J. Wei, Z. Li, C. Du, X. Zhao, H. Fu, **Y. Tian** (Changchun, P.R. China)

310. Anti-tumor activity of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines. Z. Li, C. Du, N. Tian, X. Li, X. Zhao, H. Fu, **Y. Tian** (Changchun; Hangzhou, P.R. China)
311. Curcumin induces apoptosis in human malignant glioma cell lines U251 and A172 via mitochondria-dependent pathway. Z. Li, C. Du, N. Tian, X. Li, X. Zhao, H. Fu, **Y. Tian** (Changchun; Hangzhou, P.R. China)
312. Preliminary research on significant difference gene miRNA of intracranial aneurysm wall. L. Han, D. Liu, Y. Fu, X. Zhao, **Y. Tian** (Changchun, P.R. China)
313. Spontaneous hemorrhage in children cerebellar pilocytic astrocytoma (Review). Y. Fu, X. Zhao, J. Ma, L. Han, **Y. Tian** (Changchun; Shanghai, P.R. China)
314. Aberrant RNA alternative splicing of cancer-related genes in human glioma cell lines. Z. Li, C. Du, N. Tian, X. Li, X. Zhao, H. Fu, **Y. Tian** (Changchun; Hangzhou, P.R. China)
315. The glioma-associated genes that act on RNA composition or editing on the chromosome 22q. G. Wang, L. Han, J. Gao, X. Zhao, **Y. Tian** (Changchun, P.R. China)
319. A rare case of mixed neuroendocrine tumor and adenocarcinoma of the pancreas. **S. Xenaki**, K. Lasithiotakis, M. Kouremeti, L. Rentifis, P. Papakonstantinou, G. Panagiotakis, G. Chalkiadakis (Heraklion, Greece)
320. Laparoscopic resection of lipoma of the sigmoid colon in a young patient: Case report. M. Kouremeti, L. Rentifis, S. Xenaki, N. Hadjievangeliou, K. Lasithiotakis, N. Asimakopoulou, **G. Panagiotakis**, G. Chalkiadakis (Heraklion, Greece)
328. Nuclear transport of Epstein-Barr virus DNA polymerase is dependent on the BMRF1 polymerase processivity factor and molecular chaperone Hsp90. **T. Tsurumi**, D. Kawashima (Nagoya, Japan)
330. Synergistic effect on antiproliferative and apoptotic activity by combining two different photosensitizers: *In vitro* and *in vivo* studies. **A. Villanueva**, P. Acedo, J.C. Stockert, M. Cañete, M. Camerin, G. Jori (Madrid, Spain; Padova Italy)
331. Liposomal temocene (*m*-THPPo) photodynamic treatment induces cell death by mitochondria-independent apoptosis. **M. Cañete**, M. García-Díaz, M. Mora, M.L. Sagristá, S. Nonell, A. Villanueva, J.C. Stockert, J. Soriano (Madrid; Barcelona, Spain)
335. Role of CXCL12-CXCR4/CXCR7 axis in oral squamous cell carcinoma cells. **J. Xia**, N. Chen, X. Jiang, J. Wang, Y. Hong (Guangzhou, P.R. China)
345. Chromosome correlation maps of gene expression signatures could provide useful information on gene regulatory mechanisms in urinary bladder cancer. G.I. Lambrou, M. Adamaki, D. Delakas, D.A. Spandidos, S. Vlahopoulos, **A. Zaravinos** (Athens; Heraklion, Greece; Nicosia, Cyprus)
346. Thermodynamic transitions on metabolism and proliferation of glucocorticoid-treated acute leukemia cells. **G.I. Lambrou**, A. Chatziioannou, A. Zaravinos, T. Karakonstantakis, M. Adamaki, M. Braoudaki, S.A. Vlahopoulos (Athens, Greece; Nicosia, Cyprus)
347. Computational cell membrane mechanics: An old acquaintance revisited. A. Zaravinos, A. Chatziioannou, D.A. Spandidos, **G.I. Lambrou** (Heraklion; Athens, Greece; Nicosia, Cyprus)
352. MMP-9 is down-regulated after treatment with Vemurafenib in A375 and A2058 melanoma cells. **S. Candido**, R. Salemi, F.M. Pezzino, G. Malaponte, S. Trivali, M. Libra (Catania, Italy)
353. Overexpression of Sthamin-1 in lung cancer from patients exposed to asbestos: An ‘in silico’ evaluation. **S. Candido**, R. Salemi, V. Cardile, V. Rapisarda, A. Marconi, L. Proietti, M. Libra, S. Trivali (Catania; Messina, Italy)
354. Neutrophil gelatinase-associated lipocalin (NGAL) as potential marker of bladder cancer progression. **S. Candido**, R. Salemi, F.M. Pezzino, R. Talamini, J. Polesel, J. McCubrey, S. Trivali, M. Libra (Catania; Aviano, Italy; Greenville, NC, USA)
356. V600E B-Raf mutation is associated with chemoresistance in ovarian cancer. **A.E. Russo**, I. Pellizzari, S. Candido, F.M. Pezzino, R. Sorio, G. Baldassarre, S. Canevari, J.A. McCubrey, M. Libra, A. Scalisi (Catania; Aviano; Milan, Italy; Greenville, NC, USA)

358. Prevalence and distribution of human papillomavirus in cervical samples of Cretan women. **S.P. Derdas**, E. Symvoulakis, C. Ximeris, I.N. Mamas, M. Ergazaki, E. Xenaki, A. Kalogeraki, D.A. Spandidos, G. Sourvinos (Heraklion, Greece)
359. Human papillomaviruses (HPVs) vaccination in childhood: From basic research to clinical implications. **I.N. Mamas**, N. Goulidaki, G. Sourvinos, D. Spandidos (Heraklion, Greece)
360. Human papillomavirus (HPV) vaccine uptake in childhood: A systematic review. **I.N. Mamas**, N. Goulidaki, G. Sourvinos, D. Spandidos (Heraklion, Greece)
361. George N. Papanicolaou (Greece, 1883 - U.S.A., 1962): 130th anniversary of the birth of a great doctor, scientist and humanitarian. **I.N. Mamas**, D.A. Spandidos (Heraklion, Greece)
362. MicroRNAs dramatically affect human cytomegalovirus (HCMV) lytic infection by interfering with molecular pathways of the host. **N. Goulidaki**, C. Polytarchou, D.A. Spandidos, G. Sourvinos, D. Iliopoulos (Heraklion, Greece; Los Angeles, CA; Boston, MA, USA)
363. HSV-1 controls cellular microRNAs involved in innate immune responses. **E. Tsitoura**, C. Kokkinaki, D.A. Spandidos, K.M. Antoniou, G. Sourvinos (Heraklion, Greece)
364. Expression of microRNAs involved in fibrosis in response to herpes simplex virus type-1 (HSV-1) infection in idiopathic pulmonary fibrosis. **E. Tsitoura**, K.M. Antoniou, A. Psaraki, I. Lasithiotaki, D.A. Spandidos, N.M. Sifakas, G. Sourvinos (Heraklion, Greece)
365. Investigation of BK virus (BKV), Epstein-Barr virus (EBV) and human papilloma virus (HPV) sequences in human postoperative thyroid gland specimens. **D. Stamatiou**, S. Derdas, G. Sourvinos, E. Symvoulakis, G. Sakorafas, O. Zoras, D.A. Spandidos (Heraklion; Athens, Greece)
367. Resveratrol synergizes with other polyphenolic compounds of wine to kill human colon cancer cells. F. Mazué, A. Membrilla, D. Colin, N. Latruffe, **D. Delmas** (Dijon, France)
370. Anticancer efficiency of new esters of betulin in human epidermoid cancer (A431) and melanoma (Me45). **J. Saczko**, M. Drąg-Zalesińska, J. Kulbacka, A. Choromańska, Z. Saczko, M. Poręba, M. Drąg (Wrocław, Poland)
371. Targeting signaling redundancy between the EGFR and c-MET: A novel strategy for the treatment of advanced prostate cancer. **S. Rao**, L. Peyrard, A.-L. Larroque-Lombard, B.J. Jean-Claude (Montreal, Canada)
391. Biological evaluation of psoralen derivatives as inhibitors of NF-κB/DNA interaction: Molecular modeling, 3D-QSAR, EMSA assays and inhibition of IL-8 gene expression. M. Borgatti, G. Marzaro, A. Guiotto, A. Finotti, G. Breveglieri, **R. Gambari**, A. Chilin (Ferrara; Padova, Italy)
392. Development and characterization of K562 cell clones expressing at high levels BCL11A: Induction of erythroid differentiation by mithramycin. A. Finotti, G. Breveglieri, L. Cosenza, A. Bresciani, R. Laufer, S. Altamura, N. Bianchi, E. Martini, M. Borgatti, **R. Gambari** (Ferrara; Pomezia, Italy)
393. Induction of erythroid differentiation and increased globin mRNA production with furocoumarins and their photoproducts. A. Salvador, E. Brognara, D. Vedaldi, I. Castagliuolo, P. Brun, C. Zuccato, I. Lampronti, **R. Gambari** (Padova; Ferrara, Italy)
394. Generation and molecular characterization of a transgenic mouse line carrying a mutated human β<sup>39</sup> thalassemia β-globin gene. G. Breveglieri, A. Finotti, I. Mancini, N. Bianchi, I. Lampronti, F. Salvatori, C. Zuccato, M. Borgatti, F. Altruda, S. Fagoonee, M. Iannicella, **R. Gambari** (Ferrara; Turin, Italy)
395. Peptide nucleic acids targeting miR-221 in human gliomas: Uptake and modulation of miR-221 biological functions. E. Brognara, **E. Fabbri**, E. Bazzoli, G. Montagnier, C. Ghimenton, A. Eccher, F. Aimi, A. Manicardi, N. Bianchi, A. Finotti, G. Breveglieri, M. Borgatti, R. Corradini, G. Cabrini, R. Gambari (Ferrara; Verona; Parma, Italy)
399. Expression analysis of Notch receptors family in pregnancies complicated by preeclampsia. **P. Fragiadaki**, N. Soultzis, D. Koutroulakis, N. Vrachnis, V. Gourvas, D.A. Spandidos, S. Sifakis (Heraklion; Athens, Greece)
400. MHY336, a novel 5-hydroxy-7-(oxiran-2-ylmethoxy)-2-phenyl-4 H-chromen-4-one derivative, induced apoptotic cell death and modulation of the cell cycle in HCT116 human colon cancer cells. **N.D. Kim**, Y.-J. Kang, B.K. Sung, D.-H. Kim, J.-Y. Jang, Y.J. Lee, H.R. Moon, H.Y. Chung (Busan, Republic of Korea)

401. Establishment of pancreas specific and dox inducible ICER I $\gamma$  transgenic fibroblasts in a porcine model of human diabetes mellitus. H.Y. Kang, Y.-K. Kim, **E.-B. Jeung** (Cheongju, Republic of Korea)
402. Calcium transport genes in the duodenum and kidney of catechol-O-methyltransferase-inhibited mouse model. H. Yang, E.-K. Shin, **E.-B. Jeung** (Cheongju, Republic of Korea)
403. Generation of NCKX3 knockout mice using zinc-finger nucleases. H. Yang, E.-J. Hong, **E.-B. Jeung** (Cheongju, Republic of Korea)
404. Neural differentiation of human embryonic stem cells as a tool to assess developmental neurotoxicity. H.-S. Kang, **E.-B. Jeung** (Cheongju, Republic of Korea)
405. Tight junction molecules in mouse placenta at third trimester. C. Ahn, **E.-B. Jeung** (Cheongju, Republic of Korea)
407. Uterine transient receptor potential cation channel melastatin 2 expression by gonadal steroid hormones in the estrous cycle of rats. C. Ahn, J.-S. Lee, **E.-B. Jeung** (Cheongju, Republic of Korea)
408. Effects of endocrine disruptors on streptozotocin-induced diabetic mice. H.-S. Kang, E.-J. Hong, **E.-B. Jeung** (Cheongju, Republic of Korea)
409. Effects of developmental toxic chemicals on mouse embryoid bodies. Y. Choi, **E.-B. Jeung** (Cheongju, Republic of Korea)
414. ANXA5 expression downregulation in pregnancies complicated by preeclampsia. **V. Gourvas**, N. Soultziz, A. Konstantinidou, E. Dalpa, O. Koukoura, D. Koutroulakis, D.A. Spandidos, S. Sifakis (Heraklion; Athens, Greece)
415. The expression of angiopoietins (Ang-1 and Ang-2) and their receptor TIE-1 in placentas from pregnancies complicated with preeclampsia. D. Kappou, V. Androutsopoulos, N. Papantoniou, A. Konstantinidou, D. Koutroulakis, D.A. Spandidos, **S. Sifakis** (Heraklion; Athens, Greece)
416. Placental expression of PlGF and sFlt-1 in pregnancies complicated with preeclampsia with or without fetal growth restriction. D. Kappou, V. Androutsopoulos, N. Papantoniou, A. Konstantinidou, D. Koutroulakis, D.A. Spandidos, **S. Sifakis** (Heraklion; Athens, Greece)
418. Comparison of the Cobas 4800 HPV test and the Seeplex HPV4A ACE with the hybrid capture 2 test. **S.Y. Hur**, K.H. Lee, E.Y. Ki, J.-S. Park, A. Lee (Seoul, Republic of Korea)
419. Usefulness of p16 INK4a/Ki-67 and L1 capsid protein immunostaining on ASC-H and LSIL-H of liquid-based cytology specimens. **S.W. Byun**, A.W. Lee, S. Kim, Y.J. Choi, Y.S. Lee (Seoul, Republic of Korea)
421. ADP/ATP exchange by the adenine nucleotide translocase is involved in spermine efflux from energized liver mitochondria. Molecular mechanism and pathophysiological implications. S. Grancara, P. Martinis, E. Agostinelli, G. Tempera, M. Bragadin, S. Manente, **A. Toninello** (Padova; Rome; Venice, Italy)
422. <sup>111</sup>In-Pentetreotide SPECT/CT in neuroendocrine gastroenteropancreatic (GEP) tumors. A. Spanu, F. Dore, A. Falchi, B. Piras, P. Ferro, F. Chessa, I. Gelo, L. Mele, S. Nuvoli, **G. Madeddu** (Sassari; Trieste, Italy)
423. Differentiated thyroid carcinoma (DTC) follow-up: The role of <sup>131</sup>I-SPECT/CT. A. Spanu, F. Chessa, I. Gelo, L. Mele, S. Sanna, B. Piras, S. Nuvoli, **G. Madeddu** (Sassari, Italy)
424. The usefulness of <sup>111</sup>In-Pentetreotide SPECT/CT in pulmonary carcinoid tumors (PC). A. Spanu, O. Schillaci, B. Piras, A. Falchi, R. Danieli, P. Ferro, A. Chiaravalloti, S. Nuvoli, F. Dore, **G. Madeddu** (Sassari; Trieste, Italy)
425. Preoperative identification of residual breast tumor and axillary lymph node metastases following neoadjuvant therapy: A breast scintigraphy with breast-specific  $\gamma$ -camera (BSGC) and SPECT/CT study. **A. Spanu**, F. Chessa, I. Gelo, L. Mele, G. Madeddu (Sassari, Italy)